These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1167 related items for PubMed ID: 24679337

  • 1. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [Abstract] [Full Text] [Related]

  • 2. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F.
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [Abstract] [Full Text] [Related]

  • 3. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
    Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F.
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
    [Abstract] [Full Text] [Related]

  • 4. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J, Liang J, Zhao T, Lin Y.
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [Abstract] [Full Text] [Related]

  • 5. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [Abstract] [Full Text] [Related]

  • 6. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [Abstract] [Full Text] [Related]

  • 7. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [Abstract] [Full Text] [Related]

  • 8. Response to therapy of papillary thyroid cancer of known BRAF status.
    Kowalska A, Walczyk A, Kowalik A, Pałyga I, Gąsior-Perczak D, Trybek T, Kopczyński J, Kajor M, Mikina E, Szymonek M, Gadawska-Juszczyk K, Szyska-Skrobot D, Lizis-Kolus K, Hurej S, Chrapek M, Chłopek M, Góźdź S.
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):815-824. PubMed ID: 28718951
    [Abstract] [Full Text] [Related]

  • 9. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [Abstract] [Full Text] [Related]

  • 10. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
    Lee JI, Jang HW, Kim SW, Kim JW, Oh YL, Chung JH.
    Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
    [Abstract] [Full Text] [Related]

  • 11. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M.
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [Abstract] [Full Text] [Related]

  • 13. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.
    Acta Cytol; 2011 May; 55(6):563-9. PubMed ID: 22156467
    [Abstract] [Full Text] [Related]

  • 14. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.
    Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R, Hayashi T, Arakawa A, Yao T.
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [Abstract] [Full Text] [Related]

  • 15. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B.
    PLoS One; 2015 Dec; 10(7):e0132821. PubMed ID: 26177218
    [Abstract] [Full Text] [Related]

  • 16. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A.
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [Abstract] [Full Text] [Related]

  • 17. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.
    Kowalik A, Kowalska A, Walczyk A, Chodurska R, Kopczyński J, Chrapek M, Wypiórkiewicz E, Chłopek M, Pięciak L, Gąsior-Perczak D, Pałyga I, Gruszczyński K, Nowak E, Góźdź S.
    PLoS One; 2017 May; 12(6):e0179691. PubMed ID: 28636673
    [Abstract] [Full Text] [Related]

  • 19. The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma.
    Qu HJ, Qu XY, Hu Z, Lin Y, Wang JR, Zheng CF, Tan Z.
    Endocr J; 2018 Jan 30; 65(1):113-120. PubMed ID: 29070763
    [Abstract] [Full Text] [Related]

  • 20. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
    Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY.
    Cell Physiol Biochem; 2016 Jan 30; 38(2):763-76. PubMed ID: 26871894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.